Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia

- Murray, Heather C., Miller, Kasey, Brzozowski, Joshua S., Kahl, Richard G. S., Smith, Nathan D., Humphrey, Sean J., Dun, Matthew D., Verrills, Nicole M.

Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia

- Skelding, Kathryn A., Barry, Daniel L., Theron, Danielle Z., Lincz, Lisa F.

Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study

- Ito, Tomoki, Sanford, David, Guvenc, Birol, Bui, Cat N., Delgado, Alex, Duan, Yinghui, Guijarro, Belen Garbayo, Llamas, Cynthia, Lee, Je-Hwan, Tomuleasa, Ciprian, Hsiao, Hui-Hua, Olivera, Leonardo José Enciso, Enjeti, Anoop Kumar, Conca, Alberto Gimenez, Del Castillo, Teresa Bernal, Girshova, Larisa, Martelli, Maria Paola

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia

- Murray, Heather

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors

- Smith, Amanda M., Dun, Matthew D., Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop, Verrills, Nicole M., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan